Your browser doesn't support javascript.
loading
CHIPing away the progression potential of CHIP: A new reality in the making.
Xie, Zhuoer; Zeidan, Amer M.
Afiliação
  • Xie Z; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
  • Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale Cancer Center and Smilow Cancer Hospital, Yale University School of Medicine, CT, United States. Electronic address: amer.zeidan@yale.edu.
Blood Rev ; 58: 101001, 2023 03.
Article em En | MEDLINE | ID: mdl-35989137
Over the past few years, we have gained a deeper understanding of clonal hematopoiesis of indeterminate potential (CHIP), especially with regard to the epidemiology, clinical sequelae, and mechanical aspects. However, interventional strategies to prevent or delay the potential negative consequences of CHIP remain underdeveloped. In this review, we highlight the latest updates on clonal hematopoiesis research, including molecular mechanisms and clinical implications, with a particular focus on the evolving strategies for the interventions that are being evaluated in ongoing observational and interventional trials. There remains an urgent need to formulate standardized and evidence-based recommendations and guidelines for evaluating and managing individuals with clonal hematopoiesis. In addition, patient-centric endpoints must be defined for clinical trials, which will enable us to continue the robust development of effective preventive strategies and improve clinical outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hematopoiese Clonal / Hematopoese Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hematopoiese Clonal / Hematopoese Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article